Trends of increased survival and high-grade toxicity associated with morning TMZ administration suggest consistency with the pre-clinical findings of increased glioma cell cytotoxicity at the peak of bmal1 expression and the nadir of MGMT expression—both of which seemed to demonstrate important circadian rhythms. The gene discussed is BMAL1; the disease is glioma.